Lantheus Holdings shares are trading lower after the company announced that the FDA issued a Complete Response Letter regarding its New Drug Application For LNTH-2501.

Benzinga Newsdesk www.benzinga.com Negative 96.8%

Neg 96.8% Neu 0% Pos 0%

Comments

No comments yet. Be the first!